Implementation and impact of a meningococcal C conjugate vaccination program in 13- to 25-year-old individuals in Galicia, Spain

  1. Rego Romero, Elena 1
  2. Nartallo Penas, Victoria 1
  3. Taboada Rodríguez, José Antonio 1
  4. Malvar Pintos, Alberto 1
  5. Hervada Vidal, Xurxo 1
  6. López Pimentel, María José 1
  1. 1 Dirección Xeral de Sáude Pública e Planificación, Consellería de Sanidade, Santiago de Compostela 15701 Galicia, Edificio Administrativo San Lázaro s/n, Spain
Revista:
Journal of Public Health

ISSN: 0943-1853,  1613-2238

Ano de publicación: 2011

Volume: 19

Número: 5

Páxinas: 409-415

Tipo: Artigo

DOI: 10.1007/S10389-011-0403-9 GOOGLE SCHOLAR lock_openAcceso aberto editor

Outras publicacións en: Journal of Public Health

Resumo

Background In response to increased case numbers of meningococcal group C disease, catch-up vaccination strategies have been shown to be successful. This paper describes the results of a repeat vaccination program in Galicia, Spain, and the strategy used for it. Methods and results Three vaccination waves were performed: first, in 1996/1997 with a meningococcal group A and C polysaccharide vaccine in individuals aged 18 months to 19 years; second, in 2000 with a conjugate serogroup C polysaccharide vaccine in children born since 1993 and all children and adolescents up to 19 years not previously vaccinated; third, a campaign in 2006 that became necessary because of the development of a new Neisseria strain and an increase in both the incidence and lethality of meningococcal C disease. The conjugate vaccine de-Oacetylated group C meningococcal polysaccharide coupled to tetanus toxoid was used (GCMP-TT; brand name, NeisVac-C). Results: Applying a strategy based on model calculations derived from the UK setting and focusing on a population aged 13-25 years, including students, employees of companies, and underage individuals, a total of 286,000 subjects were vaccinated, resulting in global vaccination coverage of 82.2% (all age groups over 74%). Only 17 adverse events in 17 individuals were reported, which all were mild. Incidence of meningococcal disease serogroup C by season was reduced from 0.84 cases per 100,000 in 2004/05 to 0.76 cases per 100,000 in 2005/2006 to 0.18/100,000 in 2007/08. In parallel, mortality was also decreased from 8 cases during 2005/06 (0.29 per 100,000) to 1 case in 2007/2008 (0.03 per 100,000). No cases of breakthrough disease occurred in the vaccinated population. Conclusion In Galicia, a series of vaccination campaigns, particularly focusing on high-risk groups, has shown high effectiveness, with a marked reduction in the disease incidence in the vaccination cohort accompanied by a relevant reduction in the overall population.

Referencias bibliográficas

  • Aboal Viñas JL, Farjas Abadía P, Zubizarreta Alberdi R, Hervada Vidal X, Malvar Pintos A, Amigo Quintana M, Fernández Arribas S, Moreno Molinero MJ, Taboada Rodríguez JA (1999) El procedimiento de toma de decisión para controlar la epidemia de meningitis C en Galicia en 1996. Gac Sanit 13:62–69
  • BEG Boletín Epidemilóxico de Galicia. A enfermidade Meningocócica en Galicia trala campaña de vacinación. Vol XI /1998. Num. 2. Cuadrisemana 4 a 5 /1998
  • BEG Boletín Epidemilóxico de Galicia. A enfermidade Meningocócica en Galicia: Tempada 1995/96. Vol IX / 1996. Num. 4. Cuadrisemana 7/1996
  • BEG Boletín Epidemilóxico de Galicia. A enfermidade Meningocócica en Galicia: Tempada 2001/05. Vol. XVIII / 2005 Num. 3
  • Borrow R, Findlow J (2009) Prevention of meningococcal serogroup C disease by NeisVac-C. Expert Rev Vaccines 8:265–79
  • Cano R, Larrauri A, Mateo S, Alcala B, Salcedo C, Vazquez JA (2004) Impact of the meningococcal C conjugate vaccine in Spain: an epidemiological and microbiological decision. Euro Surveill 9:11–5
  • De Wals P, De Serres G, Niyonsenga T (2001) Effectiveness of a mass immunization campaign against serogroup C meningococcal disease in Quebec. JAMA 285:177–81
  • Fernandez S, Arreaza L, Santiago I, Malvar A, Berron S, Vazquez JA, Hervada X, Gestal JJ (1999) Carriage of a new epidemic strain of Neisseria meningitidis and its relationship with the incidence of meningococcal disease in Galicia, Spain. Epidemiol Infect 123:349–57
  • Granoff DM, Gupta RK, Belshe RB, Anderson EL (1998) Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination. J Infect Dis 178:870–4
  • Pollabauer EM, Petermann R, Ehrlich HJ (2005) Group C meningococcal polysaccharide-tetanus toxoid conjugate vaccine: a meta-analysis of immunogenicity, safety and posology. Hum Vaccin 1:131–9
  • Rosenstein NE, Perkins BA, Stephens DS, Lefkowitz L, Cartter ML, Danila R, Cieslak P, Shutt KA, Popovic T, Schuchat A, Harrison LH, Reingold AL (1999) The changing epidemiology of meningococcal disease in the United States, 1992–1996. J Infect Dis 180:1894–901
  • Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME (2004) Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 364:365–7
  • Trotter CL, Gay NJ, Edmunds WJ (2005) Dynamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccination. Am J Epidemiol 162:89–100
  • Trotter CL, Ramsay ME (2007) Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines. FEMS Microbiol Rev 31:101–7
  • Trotter CL, Ramsay ME, Kaczmarski EB (2002) Meningococcal serogroup C conjugate vaccination in England and Wales: coverage and initial impact of the campaign. Commun Dis Public Health 5:220–5
  • Trotter CL, Edmunds WJ (2002) Modelling cost effectiveness of meningococcal serogroup C conjugate vaccination campaign in England and Wales. Br Med J 324:809–12
  • World Health Organization (2002) Meningococcal vaccines. Polysaccharide and polysaccharide conjugated vaccines. WHO Position Paper. Wkly Epidemiol Rec 77:331–9